论文部分内容阅读
目的:探讨缺氧诱导因子-1α(HIF-1α)在卵巢癌中的表达及其在卵巢癌化疗耐药中的作用。方法:采用免疫组化方法,检测96例卵巢癌组织,45例良性卵巢肿瘤和30例正常卵巢组织中HIF-1α的表达,分析其表达与临床病理特征及化疗耐药的相关性。结果:卵巢癌中HIF-1α的表达高于正常卵巢及良性卵巢肿瘤组织,且临床分期越晚其表达越高(P<0.001),而与肿瘤组织类型、病理分级及患者年龄无显著相关性。HIF-1α在卵巢癌化疗耐药组阳性率明显高于化疗敏感组(P<0.001)。结论:卵巢癌中HIF-1α高表达与卵巢癌的发生、发展、浸润和转移有关,与卵巢癌化疗耐药密切相关,HIF-1α可成为卵巢癌化疗新的分子治疗靶点。
Objective: To investigate the expression of hypoxia inducible factor-1α (HIF-1α) in ovarian cancer and its role in chemoresistance of ovarian cancer. Methods: The expression of HIF-1α in 96 cases of ovarian cancer, 45 cases of benign ovarian tumor and 30 cases of normal ovarian tissue was detected by immunohistochemistry. The correlation between the expression of HIF-1α and clinicopathological characteristics and chemoresistance was analyzed. Results: The expression of HIF-1α in ovarian cancer was significantly higher than that in normal ovarian and benign ovarian tumors, and the higher the clinical stage was, the higher the expression was (P <0.001). However, it had no significant correlation with tumor type, pathological grade and patient’s age . The positive rate of HIF-1α in chemotherapy-resistant ovarian cancer group was significantly higher than that in chemosensitive group (P <0.001). Conclusion: The high expression of HIF-1α in ovarian cancer is associated with the occurrence, development, infiltration and metastasis of ovarian cancer and is closely related to chemoresistance of ovarian cancer. HIF-1α may become a new molecular target of ovarian cancer chemotherapy.